01
Seven of eleven outcome trials show fewer cardiovascular events.
Each trial tests one agonist, at its dose and in its population, against placebo. LEADER, SUSTAIN-6, Harmony Outcomes, REWIND, AMPLITUDE-O, SELECT and SOUL found fewer major adverse cardiovascular events with the drug. EXSCEL's interval reached 1, and those of ELIXA, PIONEER 6 and FREEDOM-CVO crossed it. SELECT is the obesity trial: 17,604 adults with cardiovascular disease and overweight or obesity, without diabetes.
The decision
Count a trial as support only when its whole confidence interval sits below 1, and read each result as its drug's: the trials show what these agonists do to cardiovascular risk, and the receptor's own case rests on the stages that follow.
| Row | Change in hazard, % |
|---|---|
| ELIXA | 2 |
| LEADER | −13 |
| SUSTAIN-6 | −26 |
| EXSCEL | −9 |
| Harmony | −22 |
| REWIND | −12 |
| PIONEER 6 | −21 |
| AMPLITUDE-O | −27 |
| FREEDOM-CVO | 21 |
| SELECT | −20 |
| SOUL | −14 |
Every placebo-controlled trial of a GLP-1 receptor agonist with major adverse cardiovascular events as its primary outcome, published in full by 26 October 2026, in order of publication; trials against another drug, and of dual GIP and GLP-1 agonists, are left out. Change in hazard against placebo, from each hazard ratio with its 95% CI: ELIXA 1.02 (0.89 to 1.17), LEADER 0.87 (0.78 to 0.97), SUSTAIN-6 0.74 (0.58 to 0.95), EXSCEL 0.91 (0.83 to 1.00), Harmony Outcomes 0.78 (0.68 to 0.90), REWIND 0.88 (0.79 to 0.99), PIONEER 6 0.79 (0.57 to 1.11), AMPLITUDE-O 0.73 (0.58 to 0.92), FREEDOM-CVO 1.21 (0.90 to 1.63), SELECT 0.80 (0.72 to 0.90), SOUL 0.86 (0.77 to 0.96). Green where the interval stays below 1. ELIXA and FREEDOM-CVO add hospitalization for unstable angina to the composite, REWIND counts deaths of unknown cause and AMPLITUDE-O deaths of undetermined cause as cardiovascular, and FREEDOM-CVO gave exenatide by continuous subcutaneous infusion.